Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

Cancer immunology research - 1 Oct 2015

Boyerinas Benjamin, Jochems Caroline, Fantini Massimo, Heery Christopher R, Gulley James L, Tsang Kwong Yok, Schlom Jeffrey

Abstract excerpt

Several anti-PD-1/PD-L1 monoclonal antibodies (mAb) are currently providing evidence of clinical benefit in subsets of cancer patients. The mode of action of these mAbs is to inhibit PD-1 on immune cells interacting with PD-L1 on tumor cells. These mAbs are either designed or engineered to eliminate antibody-dependent cell-mediated cytotoxicity (ADCC), which, however, has been implicated as an important mechanism...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibody-Dependent Cell Cytotoxicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Interleukin-12

Share to Killer Cells, Natural

Share to Leukocytes, Mononuclear

Share to Receptors, IgG

Share to T-Lymphocytes, Cytotoxic

Source

Open in PubMed Open full text

Identifiers

PMID: 26014098
DOI: 10.1158/2326-6066.CIR-15-0059
PMCID: PMC4739754

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.PMID 26014098Read ↗

Antibody-dependent cell-mediated cytotoxicity using T cells with NK-like phenotype in combination with avelumab, an anti-PD-L1 antibody.Semantic proximity Read ↗

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagersSemantic proximity Read ↗

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibodySemantic proximity Read ↗

Anti-tumor Activity of Cetuximab Plus Avelumab in Non-Small Cell Lung Cancer Patients Involves Innate Immunity Activation: Findings from the CAVE-Lung TrialSemantic proximity Read ↗

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid LineageSemantic proximity Read ↗

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity Read ↗

Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.Semantic proximity Read ↗

CD20‐Specific Immunoligands Engaging NKG2D Enhance γδ T Cell‐Mediated Lysis of Lymphoma CellsSemantic proximity Read ↗

Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: A first-in-human phase 1 trialSemantic proximity Read ↗

Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.Semantic proximity Read ↗

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.Semantic proximity Read ↗

Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.